Filed with ASX · · 1 page · English
Cynata Therapeutics Limited has announced the receipt of a Research and Development Tax Incentive refund for the financial year, which has been used to fully repay an associated loan, leaving the company with net proceeds from the refund. The R&D TI program supports companies engaging in beneficial research and development activities in Australia, which includes Cynata's unique therapeutic products. The company is now focused on evaluating future development pathways for its Cymerus technology and exploring strategic options to realize value from it.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Cynata Therapeutics Limited ABN – 98 104 037 372 Level 3, 100 Cubitt Street Cremorne VIC 3121 Australia T: +613 7067 6940 E: [email protected] www.cynata.com ASX ANNOUNCEMENT 7 October 2026 Cynata Receives $1.7m R&D TI Refund and Repays R&D TI Loan Melbourne, Australia; 7 October 2026: Cynata...
Cynata Therapeutics Limited on 6ix
Follow Cynata Therapeutics into a list and get an email when it puts out news.
Follow Cynata Therapeutics